150 related articles for article (PubMed ID: 36423375)
1. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Dobard CW; Peet MM; Nishiura K; Holder A; Dinh C; Mitchell J; Khalil G; Pan Y; Singh ON; McCormick TJ; Agrahari V; Gupta P; Jonnalagadda S; Heneine W; Clark MR; García-Lerma JG; Doncel GF
EBioMedicine; 2022 Dec; 86():104361. PubMed ID: 36423375
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
Makarova N; Singletary T; Peet MM; Mitchell J; Holder A; Dinh C; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Smith JM; Doncel GF
EBioMedicine; 2022 Dec; 86():104338. PubMed ID: 36343572
[TBL] [Abstract][Full Text] [Related]
3. Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques.
Makarova N; Singletary T; Peet MM; Mitchell J; Bachman S; Holder A; Dinh C; Lipscomb J; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Doncel GF; Smith JM
J Infect Dis; 2024 Jun; 229(6):1791-1795. PubMed ID: 38134382
[TBL] [Abstract][Full Text] [Related]
4. Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Massud I; Ruone S; Zlotorzynska M; Haaland R; Mills P; Cong ME; Kelley K; Johnson R; Holder A; Dinh C; Khalil G; Pan Y; Kelley CF; Sanchez T; Heneine W; García-Lerma JG
EBioMedicine; 2020 Aug; 58():102894. PubMed ID: 32707451
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
6. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention.
Peet MM; Agrahari V; Clark MR; Doncel GF
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543242
[TBL] [Abstract][Full Text] [Related]
8. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Bekerman E; Cox S; Babusis D; Campigotto F; Das M; Barouch DH; Cihlar T; Callebaut C
J Antimicrob Chemother; 2021 Feb; 76(3):692-698. PubMed ID: 33202006
[TBL] [Abstract][Full Text] [Related]
9. Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection.
Massud I; Nishiura K; Ruone S; Holder A; Dinh C; Lipscomb J; Mitchell J; Khalil GM; Heneine W; Garcia-Lerma JG; Dobard CW
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543278
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Massud I; Krovi A; Nishiura K; Ruone S; Li L; Holder A; Gary J; Mills P; Mitchell J; Khalil G; Pan Y; Luecke E; Gatto G; Heneine W; García-Lerma JG; Johnson L; van der Straten A; Dobard C
J Antimicrob Chemother; 2022 Oct; 77(11):2964-2971. PubMed ID: 35913838
[TBL] [Abstract][Full Text] [Related]
11. Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.
Tsegaye TS; Butler K; Luo W; Radzio J; Srinivasan P; Sharma S; Aubert RD; Hanson DL; Dobard C; Garcia-Lerma JG; Heneine W; McNicholl JM; Kersh EN
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):385-94. PubMed ID: 25886925
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
Riddler SA; Kelly CW; Hoesley CJ; Ho KS; Piper JM; Edick S; Heard F; Doncel GF; Johnson S; Anderson PL; Brand RM; Kunjara Na Ayudhya RP; Bauermeister JA; Hillier SL; Hendrix CW
J Infect Dis; 2024 Apr; ():. PubMed ID: 38655842
[TBL] [Abstract][Full Text] [Related]
13. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
14. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
15. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
Radzio J; Aung W; Holder A; Martin A; Sweeney E; Mitchell J; Bachman S; Pau CP; Heneine W; García-Lerma JG
PLoS One; 2012; 7(12):e50632. PubMed ID: 23226529
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Mandal S; Prathipati PK; Kang G; Zhou Y; Yuan Z; Fan W; Li Q; Destache CJ
AIDS; 2017 Feb; 31(4):469-476. PubMed ID: 28121666
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
20. Development, Characterization and In Vivo Pharmacokinetic Assessment of Rectal Suppositories Containing Combination Antiretroviral Drugs for HIV Prevention.
Jhunjhunwala K; Dobard CW; Sharma S; Makarova N; Holder A; Dinh C; Mitchell J; Wang L; Zhang J; Patel SK; Heneine W; Rohan LC
Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
